1. Home
  2. PROK vs AIBZ Comparison

PROK vs AIBZ Comparison

Compare PROK & AIBZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ProKidney Corp.

PROK

ProKidney Corp.

HOLD

Current Price

$1.56

Market Cap

416.6M

Sector

Health Care

ML Signal

HOLD

AIBZ

Bitzero Holdings Inc. Common Shares

N/A

Current Price

$8.22

Market Cap

337.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
PROK
AIBZ
Founded
2015
N/A
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
416.6M
337.2M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
PROK
AIBZ
Price
$1.56
$8.22
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$7.40
N/A
AVG Volume (30 Days)
1.5M
730.2K
Earning Date
05-08-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$893,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1075.00
N/A
52 Week Low
$1.53
$6.13
52 Week High
$4.05
$9.91

Technical Indicators

Market Signals
Indicator
PROK
AIBZ
Relative Strength Index (RSI) 37.12 44.71
Support Level N/A $6.17
Resistance Level $2.59 $9.63
Average True Range (ATR) 0.17 0.99
MACD -0.03 0.06
Stochastic Oscillator 2.86 54.23

Price Performance

Historical Comparison
PROK
AIBZ

About PROK ProKidney Corp.

ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Share on Social Networks: